Imagine a world where one of the most aggressive forms of breast cancer could be tackled with a new, powerful weapon. That’s exactly what researchers at the Vall d’Hebron Institute of Oncology (VHIO) are bringing to the table with their groundbreaking discovery. In a preclinical study published in Cell Reports (https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01376-2), they’ve uncovered that Omomyc, a pioneering MYC inhibitor, can dramatically enhance the effectiveness of PARP inhibitors (PARPi) in treating triple-negative breast cancer (TNBC). But here’s where it gets even more exciting: this combination could potentially overcome drug resistance, a major hurdle in TNBC treatment.
TNBC, accounting for 15-20% of breast cancer cases, is notorious for its aggressive nature and limited treatment options. PARPi, while effective in patients with BRCA1/2 mutations (about 10-15% of TNBC cases), often face resistance over time. This is where Omomyc steps in as a game-changer. Developed by Laura Soucek and her team, Omomyc is the first and only direct MYC inhibitor to complete a phase I clinical trial. MYC, a transcription factor critical for cell division, becomes a rogue player in up to 70% of cancers, driving uncontrolled growth, metastasis, and treatment resistance. Targeting MYC has long been a holy grail in oncology, and Omomyc is leading the charge.
But this is the part most people miss: MYC’s role in DNA repair is complex and controversial. Fabio Giuntini, the study’s first author, explains, ‘MYC promotes genomic instability through replication stress, yet it also boosts certain DNA repair mechanisms. This dual role creates a delicate balance that allows cancer cells to thrive under stress.’ Omomyc disrupts this balance by increasing DNA damage in cancer cells while reducing the expression of repair genes. When combined with PARPi, the result is a synergistic anti-tumor effect, as demonstrated in both cell-derived and patient-derived xenograft models.
The data is striking: in vivo experiments showed that the Omomyc-PARPi combination achieved superior disease control compared to either treatment alone. Even more compelling, Omomyc successfully resensitized PARPi-resistant tumors, offering a potential lifeline for patients who’ve exhausted other options. And here’s a thought-provoking twist: MYC activity levels in pre-treatment tumors could predict which patients are most likely to respond to PARPi therapy. Could this be the key to personalized TNBC treatment?
This discovery isn’t just a scientific breakthrough—it’s a beacon of hope for patients battling one of the most challenging breast cancer subtypes. As Omomyc advances through clinical trials for pancreatic cancer and osteosarcoma, its potential in TNBC adds another layer of promise. But the question remains: will this combination therapy redefine how we approach drug-resistant cancers? Share your thoughts in the comments—do you think Omomyc could be the missing piece in the TNBC treatment puzzle?
